Puerarin
CAS 3681-99-0
Puerarin (CAS 3681-99-0) is a Phase 2 pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 6193.5199999999995 nM | 5 | - |
| - | Potency | 15690.166666666666 nM | 3 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPV4 TRPV4 |
Activation | 4.769999980926514 pEC50 | 33155599 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Puerarin used for in pharmaceutical contexts?
Puerarin (CAS 3681-99-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Puerarin?
No adverse-event association or SIDER side-effect rows are rendered for Puerarin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Puerarin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Puerarin with EU status "permitted".
What clinical phase is Puerarin in?
Puerarin is rendered with ChEMBL max phase 2.